Head-to-head evidence
BI 1569912 vs Esketamine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
BI 1569912
Developed by Boehringer Ingelheim
NCT06280235 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 243 participants, using the clinical MADRS depression score as its primary endpoint. However, the prespecified primary dose-response analysis was not statistically significant, so the trial provides well-controlled but inconclusive evidence of benefit.
Esketamine · Spravato
Marketed by Johnson & Johnson
NCT02417064 · Phase 3 · completed
The study randomized 346 participants to double-blind 56 mg esketamine, 84 mg esketamine, or matching placebo, each with an oral antidepressant, and used the clinical MADRS depression score as its primary endpoint. The 56 mg dose significantly outperformed placebo, while the 84 mg dose did not, so the primary results were mixed despite the strong trial design.
Next expected readout: December 2026 · NCT07369102 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BI 1569912's landscape · Esketamine's landscape